Hexagon Bio
Pre-clinicalHexagon Bio is developing novel ADC payload mechanisms to overcome resistance to today’s payloads and expand the indication space for ADCs.
Market Cap
Private
Pipeline
—
Patents
—
Publications
—
Private Company
Total funding raised: $134M
About
Hexagon Bio is developing novel ADC payload mechanisms to overcome resistance to today’s payloads and expand the indication space for ADCs.
Genetics & Genomics
Funding History
3Total raised:$134M
Series B$77MJan 15, 2022
Series A$47MAug 15, 2020
Seed$10MJun 15, 2017